UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 129

Sortiert nach

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial

JAMA ophthalmology, 2020-09, Vol.138 (9), p.964

2020

Link zum Volltext

Verfügbarkeit prüfen

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

Ophthalmology (Rochester, Minn.), 2019-08, Vol.126 (8), p.1155

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map

JAMA ophthalmology, 2022-01, Vol.140 (1), p.20

2022

Link zum Volltext

Verfügbarkeit prüfen

MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Ophthalmology (Rochester, Minn.), 2022-09, Vol.129 (9), p.974-985

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab

Cells (Basel, Switzerland), 2020-08, Vol.9 (8), p.1869

2020

Link zum Volltext

Verfügbarkeit prüfen

Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration

American journal of ophthalmology case reports, 2020-06, Vol.18, p.100680, Article 100680

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration

American journal of ophthalmology, 2021-12, Vol.232, p.49-57

2021

Link zum Volltext

Verfügbarkeit prüfen

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis

Clinical ophthalmology (Auckland, N.Z.), 2018-01, Vol.12, p.1625-1635

2018

Link zum Volltext

Verfügbarkeit prüfen

A Smart Mobile Application to Monitor Visual Function in Diabetic Retinopathy and Age-Related Macular Degeneration: The CLEAR Study

American journal of ophthalmology, 2021-07, Vol.227, p.222-230

2021

Link zum Volltext

Verfügbarkeit prüfen

Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations

American journal of ophthalmology case reports, 2020-06, Vol.18, p.100687, Article 100687

2020

Link zum Volltext

Verfügbarkeit prüfen

OPTIMAL MANAGEMENT OF PIGMENT EPITHELIAL DETACHMENTS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina (Philadelphia, Pa.), 2018-11, Vol.38 (11), p.2103

2018

Link zum Volltext

Verfügbarkeit prüfen

IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Treatment Agnostic Analysis of the HAWK and HARRIER Studies

Retina (Philadelphia, Pa.), 2023-04, Vol.43 (4), p.632

2023

Link zum Volltext

Verfügbarkeit prüfen

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

Eye (London), 2023-12, Vol.37 (17), p.3551-3557

2023

Link zum Volltext

Verfügbarkeit prüfen

Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies

Immunotherapy, 2024-03, Vol.16 (4), p.205-221

2024

Link zum Volltext

Verfügbarkeit prüfen

Home vision monitoring in patients with maculopathy: current and future options for digital technologies

Eye (London), 2023-10, Vol.37 (15), p.3108-3120

2023

Link zum Volltext

Verfügbarkeit prüfen

SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States

Ophthalmology retina, 2020-02, Vol.4 (2), p.122-133

2020

Link zum Volltext

Verfügbarkeit prüfen

Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2020-05, Vol.9 (3), p.250-259

2020

Link zum Volltext

Verfügbarkeit prüfen

Macular Telangiectasia Type 2: A Comprehensive Review

Clinical ophthalmology (Auckland, N.Z.), 2022-10, Vol.16, p.3297-3309

2022

Link zum Volltext

Verfügbarkeit prüfen

Review of gene therapies for age-related macular degeneration

Eye (London), 2022-02, Vol.36 (2), p.303-311

2022

Link zum Volltext

Verfügbarkeit prüfen

RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina (Philadelphia, Pa.), 2021-08, Vol.41 (8), p.1579

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER

British journal of ophthalmology, 2024-06, Vol.108 (6), p.852

2024

Link zum Volltext

Verfügbarkeit prüfen

Gains in the current understanding of managing neovascular AMD with brolucizumab

Journal of ophthalmic inflammation and infection, 2023-11, Vol.13 (1), p.51-51, Article 51

2023

Link zum Volltext

Verfügbarkeit prüfen

Port delivery system: a novel drug delivery platform to treat retinal diseases

Expert opinion on drug delivery, 2021-11, Vol.18 (11), p.1571-1576

2021

Link zum Volltext

Verfügbarkeit prüfen

Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data

American journal of ophthalmology, 2022-04, Vol.236, p.12-19

2022

Link zum Volltext

Verfügbarkeit prüfen

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

The Lancet (British edition), 2024-04, Vol.403 (10436), p.1563-1573

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(102)

Publikationsform

Sprache

Englisch
(129)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(81)
Science & Technology
(81)
Ophthalmology
(78)
Humans
(59)
Macular Degeneration
(32)
Visual Acuity
(32)
Vascular Endothelial Growth Factor
(29)
Intravitreal Injections
(28)
Patients
(24)
Diabetic Retinopathy
(22)
Diabetes
(20)
Female
(20)
Male
(19)
Neovascular Age-Related Macular Degeneration
(18)
Clinical Trials
(17)
Treatment Outcome
(17)
Edema
(15)
Aged
(14)
Angiogenesis Inhibitors - Therapeutic Use
(14)
Inflammation
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Ophthalmology
(12)
Clinical Ophthalmology
(11)
Journal Of Cataract And Refractive Surgery
(10)
Ophthalmology Times
(9)
Ophthalmology Retina
(8)
Retina
(6)
American Journal Of Ophthalmology
(5)
Archives Of Ophthalmology
(5)
Eye
(5)
Ophthalmology Science
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map

MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab

Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration

Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis

A Smart Mobile Application to Monitor Visual Function in Diabetic Retinopathy and Age-Related Macular Degeneration: The CLEAR Study

Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations

OPTIMAL MANAGEMENT OF PIGMENT EPITHELIAL DETACHMENTS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Treatment Agnostic Analysis of the HAWK and HARRIER Studies

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies

Home vision monitoring in patients with maculopathy: current and future options for digital technologies

SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States

Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020

Macular Telangiectasia Type 2: A Comprehensive Review

Review of gene therapies for age-related macular degeneration

RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER

Gains in the current understanding of managing neovascular AMD with brolucizumab

Port delivery system: a novel drug delivery platform to treat retinal diseases

Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

Suchergebnisse filtern